News Center

News Center

Media Spotlight | Suzhou Innovation Makes Relapse of Multiple Myeloma No Longer “Incurable”

Media Spotlight | Suzhou Innovation Makes Relapse of Multiple Myeloma No Longer “Incurable”

Multiple myeloma is the second most common hematologic malignancy, with approximately 1.6 new cases per 100,000 people in China, and it predominantly affects older adults. Data show that among individuals aged 60 and above, newly diagnosed malignant tumors account for 60.6% of all new cancer cases in the population. Every March marks International Myeloma Awareness Month. According to reports, the innovative anti-CD38 monoclonal antibody drug elotuzumab injection, used to treat multiple myeloma, was included in the National Reimbursement Drug List for the first time in 2025. Meanwhile, several biopharmaceutical companies in Suzhou are actively expanding their presence in this therapeutic area, continuously advancing the research, development, and industrialization of related drugs.

Time：2026-03-23 00:00

Professor Hong Chen: From “Glycemic Control” to “Global Control”—Redefining the Value of DPP-4 Inhibitors in the Management of Type 2 Diabetes mellitus

Professor Hong Chen: From “Glycemic Control” to “Global Control”—Redefining the Value of DPP-4 Inhibitors in the Management of Type 2 Diabetes mellitus

Against the backdrop of a steadily rising prevalence of diabetes in China and mounting pressure on prevention and control, the question of how to move beyond mere glycemic lowering toward more comprehensive glucose management and outcome optimization has become a central focus in clinical practice. In this issue, we have specially invited Professor Hong Chen from Zhujiang Hospital of Southern Medical University to provide an in-depth analysis of the current landscape of type 2 diabetes (T2DM) prevention and treatment, as well as emerging therapeutic strategies. From the evolving multi-drug landscape and patient-centered integrated management approaches to the unique safety and applicability advantages of dipeptidyl peptidase-4 inhibitors (DPP-4i), Professor Chen offers a meticulous, step-by-step exposition. In addition, drawing on key research data for the domestically developed next-generation, highly selective DPP-4i sengliptin, he systematically presents its performance and potential value in both monotherapy and combination therapy. Together, let us explore the broader possibilities and identify more optimal pathways in the pursuit of effective glucose management.

Time：2026-03-25 00:00

Science Brief | Why Are DPP-4 Inhibitors the “Reassuring Pill” for Glycemic Control in Older Patients with Diabetes?

Science Brief | Why Are DPP-4 Inhibitors the “Reassuring Pill” for Glycemic Control in Older Patients with Diabetes?

China now has more than 35 million elderly patients with type 2 diabetes. These older adults often have multiple comorbidities, take a complex regimen of medications, exhibit impaired hepatic and renal function, and are prone to muscle loss. Consequently, when selecting antidiabetic agents for this population, safety is far more critical than mere glycemic control. DPP-4 inhibitors, with their low risk of hypoglycemia, mild and kidney-friendly profile, and lack of adverse effects on muscle mass, can be used as monotherapy or in combination with other drugs, making them the first-line choice for glycemic management in elderly patients with diabetes.

Time：2026-03-24 00:00

Senglitin: A New Generation of Highly Selective DPP-4 Inhibitor in China

Senglitin: A New Generation of Highly Selective DPP-4 Inhibitor in China

Time：2026-03-19 19:45

New Information | Shengshi Taikе’s Hypoglycemic Compound Formulation Approved for Clinical Trials

New Information | Shengshi Taikе’s Hypoglycemic Compound Formulation Approved for Clinical Trials

Recently, Shengshi Taikе’s independently developed combination formulation of sengliptin phosphate and metformin hydrochloride has been approved for clinical trials, intended for type 2 diabetes patients whose glycemic control remains suboptimal despite monotherapy with metformin or who are already receiving dual therapy with the two agents. This represents another significant milestone in the company’s diabetes drug R&D pipeline, following the launch of sengliptin, a Class 1 innovative drug at the national level.

Time：2026-03-17 00:00

Shengshi Taikang Opens the Door to Capital Markets, Injecting New Momentum into Innovative Drug Development

Shengshi Taikang Opens the Door to Capital Markets, Injecting New Momentum into Innovative Drug Development

Time：2025-09-29 09:12

Renowned Experts Gather to Discuss the Ongoing Innovation of DPP-4i Therapies—National Expert Advisory Meeting on Diabetes Treatment Successfully Held under the Theme "Senhu Tang'an: Steadfastly Protecting Pancreatic Health"

Renowned Experts Gather to Discuss the Ongoing Innovation of DPP-4i Therapies—National Expert Advisory Meeting on Diabetes Treatment Successfully Held under the Theme "Senhu Tang'an: Steadfastly Protecting Pancreatic Health"

On August 22, coinciding with the 22nd Annual Conference of the Chinese Medical Association on Endocrinology (CSE 2025), the "National Expert Advisory Meeting on Diabetes Treatment—Senhutang'an: Upholding Pancreatic Health," organized by the China Medical Education Association, was successfully held. The meeting was co-chaired by Professors Li Yanli from Sun Yat-sen Memorial Hospital of Zhongshan University, Yongquan Shi from Shanghai Changzheng Hospital, Yiming Li from Huashan Hospital Affiliated to Fudan University, and Qing Su from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. It brought together numerous leading clinical experts from across the country to delve into the innovative mechanisms, evidence-based outcomes, and clinical value of Sengeletin tablets—a next-generation, highly selective dipeptidyl peptidase-4 inhibitor (DPP-4i)—providing valuable guidance and practical insights for optimizing the management of type 2 diabetes mellitus (T2DM).

Time：2025-08-28 11:54

Sipu Conference | Dr. Yu Qiang Attends the Healthcare Industry Foresight Forum, Exploring the "Unknown" from the "Known"

Sipu Conference | Dr. Yu Qiang Attends the Healthcare Industry Foresight Forum, Exploring the "Unknown" from the "Known"

Today, the second Health Industry Foresight Forum kicked off in Bo'ao, Hainan, as one of the featured forums at the 2025 West China International Fair. Grounded in the global macro trends of the health industry, the forum closely examined cutting-edge developments and future trajectories in life sciences, providing valuable insights into investment opportunities and R&D directions within the sector. Dr. Yu Qiang, Founder and CEO of Shengshi Taike, was invited to participate in the forum, where he shared his perspectives on breakthroughs and opportunities in pharmaceutical innovation, as well as emerging trends shaping the future of life sciences.

Time：2025-08-28 11:51

< 1234...8 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地